ArticleScientific reports2026
Enhancing survival risk prediction through imputation and feature selection in high-dimensional protein biomarker data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein-based molecular biomarkers play an important role in prognostic modeling and risk stratification in precision medicine. However, longitudinal survival studies involving high-dimensional biomarker data are frequently challenged by pervasive missingness and limited sample sizes, which can compromise model stability and interpretability. In this study, we present and evaluate a reproducible analytical pipeline for survival risk prediction that integrates established methods for missing data handling, feature selection, and time-to-event modeling. Missing values are addressed using an unsupervised random forest-based imputation approach that leverages internal covariate structure without incorporating outcome information, thereby reducing the risk of information leakage. Feature dimensionality is subsequently reduced using penalized Cox regression with the least absolute shrinkage and selection operator, followed by refinement and stability assessment using random survival forests to capture nonlinear effects and interactions. The final set of selected biomarkers is examined using univariate and multivariable Cox proportional hazards models to support clinical interpretability and risk stratification. Using a publicly available proteomic dataset from cancer patients, we demonstrate how this sequential modeling strategy can identify stable prognostic biomarkers while highlighting the challenges of overfitting in small-sample, high-dimensional survival settings. The proposed workflow serves as a practical and transparent framework for biomarker-driven survival analysis rather than a new statistical methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.